S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway

Centene (CNC) Competitors

$77.98
-0.45 (-0.57%)
(As of 03/1/2024 ET)

CNC vs. HUM, MOH, CI, ELV, GEHC, DXCM, IQV, ALC, TAK, and COR

Should you be buying Centene stock or one of its competitors? The main competitors of Centene include Humana (HUM), Molina Healthcare (MOH), The Cigna Group (CI), Elevance Health (ELV), GE HealthCare Technologies (GEHC), DexCom (DXCM), IQVIA (IQV), Alcon (ALC), Takeda Pharmaceutical (TAK), and Cencora (COR). These companies are all part of the "medical" sector.

Centene vs.

Humana (NYSE:HUM) and Centene (NYSE:CNC) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.

Humana has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Centene has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

91.9% of Humana shares are owned by institutional investors. Comparatively, 90.9% of Centene shares are owned by institutional investors. 0.3% of Humana shares are owned by company insiders. Comparatively, 0.3% of Centene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Humana presently has a consensus price target of $506.72, indicating a potential upside of 43.94%. Centene has a consensus price target of $83.57, indicating a potential upside of 7.17%. Given Centene's stronger consensus rating and higher probable upside, research analysts plainly believe Humana is more favorable than Centene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humana
0 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.63
Centene
0 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.55

Centene received 126 more outperform votes than Humana when rated by MarketBeat users. Likewise, 73.18% of users gave Centene an outperform vote while only 64.42% of users gave Humana an outperform vote.

CompanyUnderperformOutperform
HumanaOutperform Votes
878
64.42%
Underperform Votes
485
35.58%
CenteneOutperform Votes
1004
73.18%
Underperform Votes
368
26.82%

In the previous week, Centene had 3 more articles in the media than Humana. MarketBeat recorded 14 mentions for Centene and 11 mentions for Humana. Centene's average media sentiment score of 0.78 beat Humana's score of 0.53 indicating that Humana is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Humana
6 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Centene
5 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Humana has a net margin of 2.34% compared to Humana's net margin of 1.75%. Centene's return on equity of 19.44% beat Humana's return on equity.

Company Net Margins Return on Equity Return on Assets
Humana2.34% 19.44% 6.07%
Centene 1.75%14.26%4.36%

Centene has higher revenue and earnings than Humana. Centene is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humana$106.37B0.40$2.49B$19.8217.76
Centene$154.00B0.27$2.70B$4.9115.88

Summary

Humana beats Centene on 12 of the 18 factors compared between the two stocks.


Get Centene News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNC vs. The Competition

MetricCenteneHospital & medical service plans IndustryMedical SectorNYSE Exchange
Market Cap$41.71B$64.85B$5.09B$17.54B
Dividend YieldN/A1.30%2.82%3.57%
P/E Ratio15.8816.25221.9123.52
Price / Sales0.270.523,097.177.19
Price / Cash8.4812.2399.9215.94
Price / Book1.613.584.535.86
Net Income$2.70B$3.01B$114.85M$863.03M
7 Day Performance-2.79%-0.61%5.73%1.63%
1 Month Performance3.41%3.72%12.81%3.14%
1 Year Performance12.90%9.18%12.92%94.49%

Centene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HUM
Humana
4.9992 of 5 stars
$362.71
+0.8%
$506.72
+39.7%
-29.0%$43.76B$106.37B18.3067,600
MOH
Molina Healthcare
3.8998 of 5 stars
$400.09
-0.4%
$380.80
-4.8%
+39.4%$23.37B$34.07B21.30123,123Analyst Revision
News Coverage
CI
The Cigna Group
4.8859 of 5 stars
$340.74
-0.5%
$357.15
+4.8%
+15.8%$99.71B$195.27B19.5971,300Insider Selling
Short Interest ↑
ELV
Elevance Health
4.4119 of 5 stars
$507.63
+0.2%
$567.90
+11.9%
+6.5%$118.11B$171.34B20.17104,900Short Interest ↓
Positive News
GEHC
GE HealthCare Technologies
2.3122 of 5 stars
$92.52
+2.1%
$88.83
-4.0%
+23.6%$42.13B$19.55B30.6451,000Positive News
DXCM
DexCom
4.8239 of 5 stars
$115.32
-0.7%
$134.64
+16.8%
+0.4%$44.46B$3.62B88.039,600Short Interest ↓
IQV
IQVIA
4.8306 of 5 stars
$248.84
+0.5%
$256.80
+3.2%
+17.0%$45.41B$14.98B34.1387,000Analyst Report
Insider Selling
Short Interest ↓
Analyst Revision
ALC
Alcon
3.0492 of 5 stars
$81.26
+0.9%
$88.81
+9.3%
+27.7%$40.07B$8.72B90.2925,000Earnings Report
Analyst Report
Short Interest ↓
Analyst Revision
TAK
Takeda Pharmaceutical
2.9792 of 5 stars
$14.84
+0.2%
$21.33
+43.8%
-5.0%$46.95B$4.17T22.4849,095
COR
Cencora
4.4064 of 5 stars
$236.56
-0.7%
$214.90
-9.2%
+53.0%$47.19B$262.17B25.7746,000Analyst Revision

Related Companies and Tools

This page (NYSE:CNC) was last updated on 3/3/2024 by MarketBeat.com Staff